Claes Glassell, President and CEO of Cerus, said: “we are pleased to broaden and further strengthen our relationship with Grifols, one of the largest pharmaceutical companies in Spain and the largest European plasma fractionator.”
“Building on our success to date, we look forward to working with Grifols in Italy to increase adoption of Intercept platelets and plasma,” he added.
Riccardo Vanni, Managing Director of Grifols Italia, said: “the Intercept technology perfectly complements Grifols’ transfusion line of products in Italy and is a good fit in terms of our marketing and sales organization.”